Top Page
Emyria Ltd
(Sydney:EMD)
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Emyria Ltd Business Overview & Revenue Model
Emyria Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.39M | 2.20M | 1.59M | 1.82M | 1.98M |
| Gross Profit | 24.48K | 24.48K | -167.55K | -3.32M | -4.41M | -1.58M |
| EBITDA | -2.39M | -2.39M | -13.03M | -6.69M | -8.03M | -4.49M |
| Net Income | -3.14M | -3.14M | -11.46M | -5.13M | -7.33M | -4.91M |
Balance Sheet | ||||||
| Total Assets | 6.62M | 6.62M | 5.43M | 10.16M | 8.25M | 9.06M |
| Cash, Cash Equivalents and Short-Term Investments | 3.57M | 3.57M | 1.57M | 2.73M | 3.88M | 6.53M |
| Total Debt | 613.50K | 613.50K | 1.72M | 1.27M | 632.70K | 949.70K |
| Total Liabilities | 1.31M | 1.31M | 3.00M | 3.37M | 1.93M | 1.88M |
| Stockholders Equity | 5.31M | 5.31M | 2.43M | 6.79M | 6.32M | 7.18M |
Cash Flow | ||||||
| Free Cash Flow | -2.72M | -2.72M | -4.44M | -7.01M | -7.46M | -4.60M |
| Operating Cash Flow | -2.70M | -2.70M | -4.28M | -3.77M | -5.43M | -3.94M |
| Investing Cash Flow | 81.07K | 81.07K | -1.38M | -3.23M | -2.03M | -661.39K |
| Financing Cash Flow | 4.63M | 4.63M | 4.50M | 5.86M | 4.81M | 7.44M |
Emyria Ltd Technical Analysis
Emyria Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$21.62M | -4.65 | -27.84% | ― | 6.77% | -8.45% | |
52 Neutral | AU$21.84M | -12.11 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$49.06M | -8.71 | -81.30% | ― | -36.68% | 79.41% | |
43 Neutral | AU$78.49M | -11.01 | ― | ― | ― | ― | |
42 Neutral | AU$59.04M | -6.45 | -8647.54% | ― | 25.98% | 22.10% |
Emyria Ltd Corporate Events
Emyria Limited has applied to the ASX for quotation of 23,595 new ordinary fully paid shares under the code EMD, with an issue date of 9 January 2026. The additional securities, resulting from the exercise or conversion of existing options or other convertible securities, represent a modest capital expansion and incremental increase in Emyria’s free float, offering slightly enhanced liquidity for shareholders without materially altering the company’s capital structure.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has notified the ASX that a series of listed options (EMDAS), exercisable at $0.35 and due to expire on 22 November 2025, have lapsed. The lapse of 10,333,328 options, due to conditions not being satisfied, reduces the company’s pool of potential future equity from these instruments but does not affect its existing issued capital, providing investors with updated clarity on its capital structure.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has issued 82,785 new fully paid ordinary shares at $0.05 per share following the exercise of an equal number of options exercisable at the same price before March 2027. The company has lodged a cleansing notice under section 708A(5)(e) of the Corporations Act, confirming the shares were issued without a prospectus and that it is in compliance with its continuous disclosure and reporting obligations, enabling the new shares to be traded immediately on the ASX.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has applied to the ASX for quotation of 82,785 new fully paid ordinary shares under the code EMD. The additional securities, issued following the exercise or conversion of existing options or other convertible instruments, will modestly increase the company’s free float and share capital, providing incremental flexibility for existing holders and marginally broadening its investor base.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has issued 10 million unlisted options exercisable at $0.12 each, expiring on 27 November 2027, as part of previously announced transactions. The options, which will not be quoted on the ASX, represent a fresh tranche of unquoted equity that may provide additional capital to the company if exercised, potentially affecting its capital structure and dilution profile for existing shareholders over the medium term.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria has secured its first Victorian Empax clinic at the Mornington Peninsula, marking a significant milestone in its East Coast expansion and national clinic platform development. This expansion demonstrates Emyria’s ability to deploy its Empax clinic model consistently across jurisdictions using a capital-light, hospital-integrated framework, and active reimbursement pathways, thereby reducing execution risks and supporting revenue growth as new sites come online.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced significant progress in its Perth Clinic network, anticipating increased reimbursed clinical activity in 2026. The company has expanded its clinical capacity, with new treatment rooms and increased therapist numbers, to meet growing demand. The Perth model is set to serve as a scalable template for national expansion, particularly on the East Coast. The company is also enhancing its operations in Brisbane, with the successful onboarding of new clinical teams and the completion of initial treatments, positioning itself for substantial clinical and operational growth throughout 2026.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced the application for the quotation of 76,443 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to enhance its financial positioning and operational capabilities, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has announced the issuance of 133,333,334 new fully paid ordinary shares at an issue price of $0.06 per share, raising $8 million before costs. This capital raise allows the shares to be traded immediately under the exemption of section 708A(5) of the Corporations Act 2001, enhancing liquidity and potentially impacting the company’s market position.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced the quotation of 217,725 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 28, 2025. This move is part of the company’s strategy to enhance its financial flexibility and operational capacity, potentially strengthening its position in the healthcare market and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced the quotation of 133,333,334 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EMD, effective from November 28, 2025. This move follows previous transactions and is part of the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its operational dynamics and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has announced the issuance of 916,667 new fully paid ordinary shares at an issue price of $0.05 per share following the exercise of options. This issuance allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001, indicating compliance with relevant legal provisions and facilitating liquidity for stakeholders.
Emyria Ltd has announced the quotation of 1,388,316 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of November 21, 2025. This development is part of the company’s strategy to enhance its market presence and potentially increase its capital base, which could have significant implications for its stakeholders and industry positioning.
Emyria Ltd has announced a proposed issue of securities, including 10 million unlisted options and over 133 million ordinary fully paid shares. This move is part of a placement or other type of issue, with the proposed issue date set for November 28, 2025. The issuance is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for growth and expansion.
Emyria Limited has announced a significant expansion of its national presence by exercising an option to establish its first Empax Clinic in Victoria, marking a major milestone in its East Coast expansion. The company has secured exclusive rights to roll out Empax clinics across Avive Health’s network, enhancing its ability to provide intensive mental-health services nationwide. This expansion is supported by a successful $8 million institutional placement, which will accelerate the development of new sites and expand the clinical workforce. Additionally, Emyria has commenced revenue generation at its Brisbane clinic and has received support from the Department of Veterans’ Affairs for medication-assisted therapy, establishing a dual reimbursement pathway with private insurers.
Emyria Ltd has announced the quotation of 730,114 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EMD. This move is part of the company’s strategy to enhance its market presence and provide more liquidity for its shareholders, potentially impacting its operational capacity and investor relations positively.
Emyria Limited announced that all resolutions presented at their Annual General Meeting were successfully carried by a poll. The resolutions included matters such as the remuneration report, election of a director, and approval of a 10% placement facility, among others. This outcome reflects strong shareholder support and may positively impact the company’s governance and strategic initiatives.
Emyria Ltd has announced the quotation of 322,976 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 7, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market positioning and providing new opportunities for stakeholders.
Emyria Ltd has announced the cessation of 300,000 securities due to the expiry of options that were not exercised or converted by November 1, 2025. This development may affect the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s financial instruments.
Emyria Limited has reported significant growth in revenue and operational expansion in its quarterly activity report for September 2025. The company has expanded its agreement with Medibank to include insurer-funded access to its mental health treatment programs for PTSD and TRD in both Perth and Brisbane. This expansion marks the first national rollout of insured mental health treatment programs in Australia, demonstrating strong insurer confidence in Emyria’s care model. The company has also increased its workforce and treatment capacity to support growing demand, with plans to commence patient dosing in Brisbane by late Q4 2025. Emyria’s strategic partnerships and scalable model position it as a leader in evidence-based mental health care, with ongoing commercial momentum and broader national rollout plans.
Emyria Ltd has announced the quotation of 278,113 fully paid ordinary securities on the Australian Securities Exchange (ASX), following the exercise of options or conversion of other convertible securities. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operations and positioning within the healthcare sector.
Emyria Limited has announced the issuance of 845,979 new fully paid ordinary shares at an issue price of $0.05 per share, following the exercise of options. This move allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001, enhancing liquidity and potentially strengthening the company’s financial position. The announcement signifies Emyria’s compliance with relevant legal provisions, ensuring transparency and adherence to corporate governance standards.
Emyria Ltd has announced the quotation of 2,524,780 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from October 17, 2025. This move signifies a strategic step for Emyria in expanding its capital base, potentially enhancing its market position and providing additional resources to further its healthcare initiatives.
Emyria Limited has announced a significant expansion of its services with a new funding agreement from Medibank Private Ltd. This agreement will allow eligible patients to access Emyria’s mental health programs for TRD and PTSD at the new Empax Clinic in Brisbane, marking the company’s first insurer-backed services on Australia’s East Coast. This expansion is part of Emyria’s national growth strategy to address the mental health burden in Australia by providing affordable and coordinated treatment options. The collaboration with Medibank is expected to reduce financial barriers for patients and demonstrates the scalability of Emyria’s care model, positioning the company as a leader in evidence-based mental health care.
Emyria Ltd has announced its involvement in addressing Australia’s mental health crisis through the development of advanced therapies, including the use of MDMA and psilocybin in psychedelic-assisted psychotherapy. While these treatments show promise, they are subject to clinical trials to ensure safety and efficacy, and currently, no approved products exist. The announcement highlights Emyria’s commitment to innovative mental health solutions, although it also underscores the risks and uncertainties inherent in developing such treatments.
Emyria Limited announced its participation in a live investor webinar hosted by Sharewise, where key executives will discuss the company’s latest developments and strategic outlook. The webinar will cover Emyria’s unique positioning in delivering evidence-based treatments, national expansion plans, and growth strategy, providing stakeholders with insights into the company’s future directions.
Emyria Ltd has announced the quotation of 112,610 ordinary fully paid securities on the ASX, effective October 10, 2025. This move signifies the company’s strategic efforts to enhance its capital structure and potentially increase its market presence, which could have implications for its stakeholders and industry positioning.
Emyria Ltd, a company listed on the ASX under the ticker EMD, is making significant strides in addressing serious mental illnesses. The company’s efforts are positively impacting the lives of patients and their communities, as highlighted by Executive Chairman Greg Hutchinson. This mission-driven approach underscores Emyria’s commitment to improving mental health outcomes.
Emyria Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, indicating a commitment to transparency and accountability in its management and oversight practices.
Emyria Ltd has announced its upcoming Annual General Meeting (AGM) for shareholders, scheduled for November 13, 2025, in West Perth, Australia. The company has opted for electronic distribution of the meeting materials, encouraging shareholders to vote by proxy if unable to attend in person. This move reflects a modern approach to shareholder engagement, potentially enhancing participation and operational efficiency.
Emyria Ltd has announced its Annual General Meeting (AGM) scheduled for November 13, 2025, at Stantons International in West Perth, Australia. The AGM will address the company’s annual report and include resolutions on the remuneration report and the election of Dr. Michael Winlo as a director. Shareholders are encouraged to participate and vote, with the meeting set to discuss key governance and strategic decisions impacting the company’s future direction.